- Home
- MGTX
as 02-21-2025 4:00pm EST
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 479.9M | IPO Year: | N/A |
| Target Price: | $23.50 | AVG Volume (30 days): | 257.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.85 - $7.80 | Next Earning Date: | 03-13-2025 |
| Revenue: | $13,929,000 | Revenue Growth: | 108.24% |
| Revenue Growth (this year): | -2.53% | Revenue Growth (next year): | 1391.84% |
Stock Insider Trading Activity of MeiraGTx Holdings plc (MGTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Giroux Richard | MGTX | CFO & COO | Jan 21 '25 | Sell | $6.29 | 24,000 | $150,960.00 | 849,947 | |
| Forbes Alexandria | MGTX | PRESIDENT & CEO | Jan 7 '25 | Sell | $6.39 | 47,500 | $305,342.63 | 1,395,102 |
Latest MeiraGTx Holdings plc News
MGTX Breaking Stock News: Dive into MGTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy
Simply Wall St.
24 days ago
MeiraGTx Holdings plc's (NASDAQ:MGTX) top owners are private equity firms with 25% stake, while 21% is held by institutions
MT Newswires
a month ago
MeiraGTx Says FDA Grants Rare Pediatric Disease Designation to Eye Disorder Drug
GlobeNewswire
a month ago
MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations
Insider Monkey
a month ago
Is MeiraGTx Holdings plc (MGTX) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?
Simply Wall St.
2 months ago
High Growth Tech Stocks in the United States
Insider Monkey
2 months ago
MeiraGTx Holdings plc (MGTX): Is This Gene Therapy Stock a Good Buy Right Now?
Simply Wall St.
2 months ago
Investors in MeiraGTx Holdings (NASDAQ:MGTX) have unfortunately lost 71% over the last five years
Compare MGTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MGTX MeiraGTx Holdings plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.